Company Eretupinab S.r.l. with Fiscal Code 38874679
recorded a turnover of 2024 of
463.792,
with a net profit of
-125.439
and having an average number of employees of
13.
The company operates in the field of Lucrări de construcţii a clădirilor rezidenţiale şi nerezidenţiale having the NACE code 4100.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Eretupinab S.r.l.
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
-
-
-
65.419
301.632
798.350
983.470
1.136.022
377.579
463.792
Total Income - EUR
-
-
-
65.419
301.814
798.941
983.486
1.140.272
378.317
465.144
Total Expenses - EUR
-
-
-
34.695
188.530
497.800
895.132
972.112
385.078
590.582
Gross Profit/Loss - EUR
-
-
-
30.724
113.283
301.141
88.354
168.160
-6.761
-125.439
Net Profit/Loss - EUR
-
-
-
30.070
110.265
293.612
78.788
156.517
-11.297
-125.439
Employees
-
-
-
4
9
10
11
13
12
13
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 23.5%, from 377.579 euro in the year 2023, to 463.792 euro in 2024.
Check the financial reports for the company - Eretupinab S.r.l.
Financial Rating - ERETUPINAB S.R.L.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Eretupinab S.r.l.
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Eretupinab S.r.l.
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Eretupinab S.r.l.
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
49.157 euro in 2024 which includes Inventories of
8.269 euro, Receivables of
11.701 euro and cash availability of
29.187 euro.
The company's Equity was valued at
-136.624 euro, while total Liabilities amounted to
210.363 euro.
Equity decreased by -125.439 euro, from -11.248 euro in 2023, to -136.624 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Eretupinab S.r.l.